Predicting routes of phase I and II metabolism based on quantum mechanics and machine learning

References

• Bauman JN, Doran AC, King-Ahmad A, Sharma R, Walker GS, Lin J, Lin TH, Telliez JB, Tripathy S, Goosen TC, Banfield C, Malhotra BK, Dowty ME. 2022. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans. Drug Metab. Dispos. 50(3):1106–1118.
   Google Scholar
• Beers JL, Fu D, Jackson KD. 2021. Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol Drug Metab. Dispos. 49(10):882–891.
   Google Scholar
• Cai Y, Yang H, Li W, Liu G, Lee PW, Tang Y. 2019. Computational prediction of site of metabolism for UGT-Catalyzed reactions. J. Chem. Inf. Model. 59(3):1085–1095.
   Google Scholar
• Choi SM, Kim Y, Lee J, Kim JH, Lee T, Min BS, Kim JA, Lee S. 2020. Characterization of hydrocoptisonine metabolites in human liver microsomes using a high-resolution quadrupole-orbitrap mass spectrometer. Xenobiotica 50(12):1423–1433.
   Google Scholar
• Cruciani G, Carosati E, De Boeck B, Ethirajulu K, Mackie C. Howe T, Vianello R. 2005. MetaSite: understanding metabolism in human Cytochromes from the perspective of the chemist. J. Med. Chem. 48(22):6970–6979.
   Google Scholar
• Dang NL, Hughes TB, Krishnamurthy V, Swamidass SJ. 2016. a simple model predicts UGT-mediated metabolism. Bioinformatics. 32(20):3183–3189.
   Google Scholar
• De Gregor S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi M. 2012. Morphine metabolism, transport and brain disposition. Metab. Brain Dis. 27(1):1–5.
   Google Scholar
• de Vries R, Jacobs F, Mannens G, Snoeys J, Cuyckens F, Chien C, Ward P. 2019. Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes. Drug Metab. Dispos. 47(5):453–464.
   Google Scholar
• Dixit VA, Lal LA, Agrawal SR. 2017. Recent advances in the prediction of non‐cyp450‐mediated drug metabolism. WIREs Computational Molecular Science. e1323.
   Google Scholar
• Djoumbou-Feunang Y, Fiamoncini J, Gil-de-la-Fuente A, Greiner R, Manach C, Wishart DS. 2019. BioTransformer: a comprehensive computational tool for small molecule metabolism prediction and metabolite identification. J. Cheminf. 11(2):1–25.
   Google Scholar
• Dowden H and Munro J. 2019. Trends in clinical success rates and therapeutic focus. Nat. Rev. Drug Discovery. 18:495–496.
   Google Scholar
• Dumouchel JL, Argikar UA, Adams CM, Prasanna G, Ehara T, Kim S, Breen C, Mogi M. 2021. Understanding metabolism related differences in ocular efficacy of MGV354. Xenobiotica 51(1):5–14.
   Google Scholar
• Fu CW, Lin TH. 2017. Predicting the metabolic sites by Flavin-containing Monooxygenase on drug molecules using SVM classification on computed quantum mechanics and circular fingerprints molecular descriptors. PLOS ONE. 12(1):e0169910.
   Google Scholar
• Glaenzel U, Jin Y, Hansen R, Schroer K, Rahmanzadeh G, Pfaar U, van Lier JJ, Borell H, Meissner A, Camenisch G, Zhao S. 2020. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite. Drug Metab. Dispos. 48(10):873–885.
   Google Scholar
• Guengerich FP. 2006. Cytochrome P450s and other enzymes in drug metabolism and toxicity. An Official Journal of the American Association of Pharmaceutical Scientists. 8:E101–E111.
   Google Scholar
• Guengerich FP. 2008. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 21(1):70–83.
   Google Scholar
• Liao M, Jaw-Tsai S, Beltman J, Simmons AD, Harding TC, Xiao JJ. 2020. Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose). Xenobiotica 50(9):1032–1042.
   Google Scholar
• Hanioka N, Isobe T, Tanaka-Kagawa T, Ohkawara S. 2020. Wogonin glucuronidation in liver and intestinal microsomes of humans, monkeys, dogs, rats, and mice. Xenobiotica 50(8):906–912.
   Google Scholar
• Hennemann M, Friedl A, Lobell M, Keldenich J, Hillisch A, Clark T, Göller AH. 2009. CypScore: quantitative prediction of reactivity toward Cytochromes P450 based on semiempirical molecular orbital theory. ChemMedChem. 4(4):657–669.
   Google Scholar
• Hinkson IV, Madej B, Stahlberg EA. 2020. Accelerating therapeutics for opportunities in medicine: a paradigm shift in drug discovery. Front. Pharmacol. 11:1–7.
   Google Scholar
• Hunt PA, Segall MD, Tyzack JD. 2018. WhichP450: a multi-class categorical model to predict the major metabolising CYP450 isoform for a compound. J. Comput.-Aided Mol. Des. 32:537–546.
   Google Scholar
• Hussain Z, Zhu J, Ma X. 2021. Metabolism and hepatotoxicity of pyrazinamide, an anti-tuberculosis drug. Drug Metab. Dispos. 49(8):679–682.
   Google Scholar
• Hutzler JM, Cerny MA, Yang YS, Asher C, Wong D, Frederick K, Gilpin K. 2014. Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382. Drug Metab. Dispos. 42(10):1751–1760.
   Google Scholar
• Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. 2019. Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica 49(12):1388–1395.
   Google Scholar
• Katyayan K, Yi P, Monk S, Cassidy K. 2020 Excretion, Mass Balance, and Metabolism of [14C]LY3202626 in Humans: An Interplay of Microbial Reduction, Reabsorption, and Aldehyde Oxidase Oxidation That Leads to an Extended Excretion Profile. Drug Metab. Dispos. 48(8):698–707.
   Google Scholar
• Kennedy T. 1997. Managing the drug discovery/development interface. Drug Discovery Today. 2(10):436–444.
   Google Scholar
• Kim Y, Shrestha R, Kim S, Kim JA, Lee J, Jeong TC, Kim JH, Lee S. 2020. In vitro characterization of glycyrol metabolites in human liver microsomes using HR-resolution MS spectrometer coupled with tandem mass spectrometry. Xenobiotica 50(4):380–388.
   Google Scholar
• Lapham K, Callegari E, Cianfrogna J, Lin J, Niosi M, Orozco CC, Sharma R, Goosen TC. 2020. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes. Drug Metab. Dispos. 48(12):1350–1363.
   Google Scholar
• van der Maaten L, Hinton G. 2008. Visualizing Data using t-SNE. J. Mach. Learn. Res. 9(86):2579 − 2605
   Google Scholar
• Marchant CA, Briggs KA, Long A. 2008. In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for Windows, Meteor, and Vitic. Toxicol. Mech. Methods. 18(2–3):177–187.
   Google Scholar
• Matsumoto K, Hasegawa T, Ohara K, Kamei T, Koyanagi J, Akimoto M. 2021. Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer–Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid in vitro. Xenobiotica 51(2):155–166.
   Google Scholar
• Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. 2019. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 47(D1):D930–D940.
   Google Scholar
• Milani N, Qiu N, Fowler S. 2022. Contribution of UGT enzymes to human drug metabolism stereoselectivity: a case study of medetomidine, RO5263397, propranolol and testosterone. Drug Metab. Dispos. 51(3):306–317.
   Google Scholar
• Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. 1990. Torsades de pointes occurring in association with terfenadine use. The Journal of the American Medical Association. 264(21):2788–2790.
   Google Scholar
• Montefiori M, Jørgensen FS, Olsen L. 2017. Aldehyde Oxidase: reaction mechanism and prediction of site of metabolism. ACS Omega. 2(8):4237–4244.
   Google Scholar
• Montefiori M, Lyngholm-Kjaerby C, Long A, Olsen L, Jørgensen FS. 2019. Fast methods for prediction of Aldehyde Oxidase-mediated site-of-metabolism. Comput. Struct. Biotechnol. J. 17:345–351.
   Google Scholar
• Nardone-White DT, Bissada JE, Abouda AA, Jackson KD. 2021. Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib. Drug Metab. Dispos. 49(3):233–244.
   Google Scholar
• Obrezanova O, Gola JMR, Champness EJ, Segall MD. 2008. Automatic QSAR modeling of ADME properties: blood–brain barrier penetration and aqueous solubility. J. Comput.-Aided Mol. Des. 22:431–440.
   Google Scholar
• Omura K, Motoki K, Kobashi S, Miyata K, Yamano K, Iwanaga T. 2021. Identification of Human UDP-Glucuronosyltransferase and Sulfotransferase as Responsible for the Metabolism of Dotinurad, a Novel Selective Urate Reabsorption Inhibitor. Drug Metab. Dispos. 51(3):1016–1024.
   Google Scholar
• Öeren M, Kaempf SC, Ponting DJ, Hunt PA, Segall MD. 2023. predicting regioselectivity of cytosolic Sulfotransferase metabolism for drugs. Journal of Chemical Information and Modeling. 63(11):3340–3349.
   Google Scholar
• Öeren M, Walton PJ, Hunt PA, Ponting DJ, Segall MD. 2020. Predicting reactivity to drug metabolism: beyond P450s—modelling FMOs and UGTs. J. Comput.-Aided Mol. Des. 35:541–555.
   Google Scholar
• Öeren M, Walton PJ, Suri J, Ponting DJ, Hunt PA, Segall MD. 2022. Predicting regioselectivity of AO, CYP, FMO, and UGT metabolism using quantum mechanical simulations and machine learning. J. Med. Chem. 65(20):14066–14081.
   Google Scholar
• Olsen L, Montefiori M, Tran KP, Jørgensen FS. 2019. SMARTCyp 3.0: enhanced Cytochrome P450 site-of-metabolism prediction server. Bioinformatics. 35(17): 3174–3175.
   Google Scholar
• Peng J, Lu J, Shen Q, Zheng M, Luo X, Zhu W, Jiang H, Chen K. 2013. In silico site of metabolism prediction for human UGT-catalyzed reactions. Bioinformatics 30(3): 398–405.
   Google Scholar
• Rudik A, Dmitriev A, Lagunin A, Filimonov D, Poroikov V. 2015. SOMP: web server for in silico prediction of sites of metabolism for drug-like compounds. Bioinformatics. 31(12):2046–2048.
   Google Scholar
• Saravanakumar A, Sadighi A, Ryu R, Akhlaghi F. 2019. Physicochemical properties, biotransformation, and transport pathways of established and newly approved medications: a systematic review of the top 200 most prescribed drugs vs. the FDA-approved drugs between 2005 and 2016. Clin. Pharmacokinet. 58:1281–1294.
   Google Scholar
• Scheers E, Borgmans C, Keung C, Bohets H, Wynant I, Poggesi I, Cuyckens F, Leclercq L, Mamidi RNVS. 2020. Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. Xenobiotica 51(2):177–193.
   Google Scholar
• Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M. 2021. How much does it cost to research and develop a new drug? A systematic review and assessment. PharmacoEconomics. 39:1243–1269.
   Google Scholar
• Seo KA, Bae KS, Choi YK, Choi CS, Liu KH, Shin JG. 2010. Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab. Dispos. 38(11): 2007–2013.
   Google Scholar
• Shih HP, Zhang X, Aronov AM. 2018. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat. Rev. Drug Discovery. 17:19–33.
   Google Scholar
• Šícho M, de Bruyn Kops C, Stork C, Svozil D, Kirchmair J. 2017. FAME 2: simple and effective machine learning model of Cytochrome P450 regioselectivity. The Journal of Chemical Information and Modeling. 57(8):1832–1846.
   Google Scholar
• SMARTS - A Language for Describing Molecular Patterns. 2019. Laguna Niguel (CA): Daylight Chemical Information Systems, Inc. [accessed 2023 July 03]. https://www.daylight.com/dayhtml/doc/theory/theory.smarts.html.
   Google Scholar
• Sorich MJ, McKinnon RA, Miners JO, Smith PA. 2006. The importance of local chemical structure for chemical metabolism by human Uridine 5'-diphosphate-glucuronosyltransferase. J. Chem. Inf. Model. 46(6):2692–2697.
   Google Scholar
• Schuster D, Laggner C, Langer T. 2005. Why Drugs Fail - A Study on Side Effects in New Chemical Entities. Curr. Pharmaceutical Des. 11(27): 3545–3559
   Google Scholar
• Sun D, Gao W, Hu H, Zhou S. 2022. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B. 12(7):3049–3062.
   Google Scholar
• Surapaneni S, Yerramilli U, Bai A, Dalvie D, Brooks J, Wang X, Selkirk JV, Yan YG, Zhang P, Hargreaves R, Kumar G, Palmisano M, Tran JQ. 2021. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator. Drug Metab. Dispos. 49(5):405–419.
   Google Scholar
• Taavitsainen P, Prien O, Kähkönen M, Niehues M, Korjamo T, Denner K, Nykänen P, Vuorela A, Jungmann NA, von Bühler CJ, Koskinen M, Zurth C, Gieschen H. 2021. Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans. Drug Metab. Dispos. 49(6):420–433.
   Google Scholar
• Takabe T, Imai R, Ono S. 2017. The current status of drug discovery and development as originated in united states academia: the influence of industrial and academic collaboration on drug discovery and development. Clin. Transl. Sci. 11(6):597–606.
   Google Scholar
• Tian S, Cao X, Greiner R, Li C, Guo A, Wishart DS. 2021. CyProduct: a software tool for accurately predicting the byproducts of human Cytochrome P450 metabolism. Journal of Chemical Information and Modelling. 61(6):3128–3140.
   Google Scholar
• Tian S, Djoumbou-Feunang Y, Greiner R, Wishart DS. 2018. CypReact: a software tool for in silico reactant prediction for human Cytochrome P450 enzymes. The Journal of Chemical Information and Modelling. 58(6):1282–1291.
   Google Scholar
• T’jollyn H, Boussery K, Mortishire-Smith RJ, Coe K, De Boeck B, Van Bocxlaer JF, Mannens G. 2011. Evaluation of three state-of-the-art metabolite prediction software packages (Meteor, MetaSite, and Stardrop) through independent and synergistic use. Drug Metab. Dispos. 39(11):2066–2075.
   Google Scholar
• Tyzack JD, Hunt PA, Segall MD. 2016. Predicting regioselectivity and lability of cytochrome P450 metabolism using quantum mechanical simulations. J. Chem. Inf. Model. 56(11):2180–2193.
   Google Scholar
• Vaillancourt J, Turcotte V, Caron P, Villeneuve L, Lacombe L, Pouliot F, Lévesque É, Guillemette C. 2020. Glucuronidation of Abiraterone and its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and their Potential as Inhibitors of Steroid Glucuronidation. Drug Metab. Dispos. 48(2):75–84.
   Google Scholar
• Veeravalli S, Phillips IR, Freire RT, Varshavi D, Everett JR, Shephard EA. 2020. Flavin-Containing Monooxygenase 1 (FMO1) Catalyzes the Production of Taurine from Hypotaurine. Drug Metab. Dispos. 48(5):378–385.
   Google Scholar
• Weiss HM, Langenickel T, Cain M, Kulkarni S, Shah B, Vemula J, Rahmanzadeh G, Poller B. 2021. Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator. Drug Metab. Dispos. 49(5):389–394.
   Google Scholar
• Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. 2004. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCI/AUC) ratios. Drug Metab. Dispos. 32(11):1201–1208.
   Google Scholar
• Wouters OJ, McKee M, Luyten J. 2020. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. Journal of the American Medical Association. 323(9): 844–853.
   Google Scholar
• Yamane M, Igarashi F, Yamauchi T, Nakagawa T. 2021. Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout. Xenobiotica 51(1):61–71.
   Google Scholar
• Yu C. 2020. Metabolism and in vitro drug–drug interaction assessment of viloxazine. Xenobiotica 50(11):1285–1300.
   Google Scholar
• Zanger UM and Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138(1):103–141.
   Google Scholar
• Zaretzki J, Matlock M, Swamidass SJ. 2013. XenoSite: Accurately Predicting CYP-Mediated Sites of Metabolism with Neural Networks XenoSite: accurately predicting CYP-mediated sites of metabolism with neural networks. The Journal of Chemical Information and Modelling. 53(12):3373–3383.
   Google Scholar
• Zhang L, Poland B, Green M, Wong S, Slatter JG. 2022. A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1). Xenobiotica 52(6):555–566.
   Google Scholar